Which has higher earnings & valuation, CAH or COR?

Cencora has higher revenue and earnings than Cardinal Health. Cencora is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $254.25B 0.26 $1.71B $7.73 36.42 Cencora $337.40B 0.20 $3.48B $17.92 20.04

Does the media favor CAH or COR?

In the previous week, Cardinal Health had 11 more articles in the media than Cencora. MarketBeat recorded 24 mentions for Cardinal Health and 13 mentions for Cencora. Cardinal Health's average media sentiment score of 0.83 beat Cencora's score of 0.83 indicating that Cardinal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 12 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cencora 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COR or ELV?

In the previous week, Elevance Health had 9 more articles in the media than Cencora. MarketBeat recorded 22 mentions for Elevance Health and 13 mentions for Cencora. Elevance Health's average media sentiment score of 0.87 beat Cencora's score of 0.83 indicating that Elevance Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Elevance Health 14 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, COR or MCK?

McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cencora $337.40B 0.20 $3.48B $17.92 20.04 McKesson $403.43B 0.32 $4.76B $38.89 28.37

Is COR or MCK more profitable?

McKesson has a net margin of 1.12% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat McKesson's return on equity. Company Net Margins Return on Equity Return on Assets Cencora 1.03% 110.72% 4.22% McKesson 1.12% -202.94% 5.92%

Does the media refer more to COR or MCK?

In the previous week, McKesson had 16 more articles in the media than Cencora. MarketBeat recorded 29 mentions for McKesson and 13 mentions for Cencora. McKesson's average media sentiment score of 0.98 beat Cencora's score of 0.83 indicating that McKesson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive McKesson 20 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, COR or HSIC?

Cencora has higher revenue and earnings than Henry Schein. Cencora is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cencora $337.40B 0.20 $3.48B $17.92 20.04 Henry Schein $13.18B 0.72 $398M $3.65 23.62

Is COR or HSIC more profitable?

Henry Schein has a net margin of 3.07% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Cencora 1.03% 110.72% 4.22% Henry Schein 3.07% 16.39% 5.58%

Which has preferable valuation & earnings, COR or AHCO?

Cencora has higher revenue and earnings than AdaptHealth. AdaptHealth is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cencora $337.40B 0.20 $3.48B $17.92 20.04 AdaptHealth $3.24B 0.32 -$70.79M -$3.00 N/A

Does the media refer more to COR or AHCO?

In the previous week, Cencora had 5 more articles in the media than AdaptHealth. MarketBeat recorded 13 mentions for Cencora and 8 mentions for AdaptHealth. Cencora's average media sentiment score of 0.83 beat AdaptHealth's score of 0.29 indicating that Cencora is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AdaptHealth 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cencora (COR) Competitors

$359.12 +9.74 (+2.79%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$359.02 -0.10 (-0.03%)

As of 11/13/2026 07:30 PM Eastern

Compare

COR vs. CAH, ELV, MCK, HSIC, and AHCO

Should you buy Cencora stock or one of its competitors? Cencora's main competitors and comparable companies include Cardinal Health (CAH), Elevance Health (ELV), McKesson (MCK), Henry Schein (HSIC), and AdaptHealth (AHCO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Cencora compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Cencora (NYSE:COR) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

87.2% of Cardinal Health shares are held by institutional investors. Comparatively, 97.5% of Cencora shares are held by institutional investors. 0.1% of Cardinal Health shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cencora has higher revenue and earnings than Cardinal Health. Cencora is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$254.25B	0.26	$1.71B	$7.73	36.42
Cencora	$337.40B	0.20	$3.48B	$17.92	20.04

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.7%. Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. Cardinal Health pays out 26.6% of its earnings in the form of a dividend. Cencora pays out 13.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years and Cencora has raised its dividend for 15 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Cardinal Health currently has a consensus price target of $279.44, suggesting a potential downside of 0.75%. Cencora has a consensus price target of $368.14, suggesting a potential upside of 2.51%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Cencora	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75

Cencora has a net margin of 1.03% compared to Cardinal Health's net margin of 0.71%. Cencora's return on equity of 110.72% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.71%	-102.72%	4.86%
Cencora	1.03%	110.72%	4.22%

Cardinal Health has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Cencora has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Cardinal Health had 11 more articles in the media than Cencora. MarketBeat recorded 24 mentions for Cardinal Health and 13 mentions for Cencora. Cardinal Health's average media sentiment score of 0.83 beat Cencora's score of 0.83 indicating that Cardinal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cencora	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardinal Health and Cencora tied by winning 10 of the 20 factors compared between the two stocks.

How does Cencora compare to Elevance Health?

Cencora (NYSE:COR) and Elevance Health (NYSE:ELV) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Elevance Health has a net margin of 2.55% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	1.03%	110.72%	4.22%
Elevance Health	2.55%	14.97%	5.31%

In the previous week, Elevance Health had 9 more articles in the media than Cencora. MarketBeat recorded 22 mentions for Elevance Health and 13 mentions for Cencora. Elevance Health's average media sentiment score of 0.87 beat Cencora's score of 0.83 indicating that Elevance Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cencora	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Elevance Health	14 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cencora has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Elevance Health has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Cencora currently has a consensus price target of $368.14, indicating a potential upside of 2.51%. Elevance Health has a consensus price target of $456.48, indicating a potential upside of 6.28%. Given Elevance Health's higher probable upside, analysts clearly believe Elevance Health is more favorable than Cencora.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75
Elevance Health	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.68

97.5% of Cencora shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 0.4% of Cencora shares are held by insiders. Comparatively, 0.3% of Elevance Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. Elevance Health pays an annual dividend of $6.88 per share and has a dividend yield of 1.6%. Cencora pays out 13.4% of its earnings in the form of a dividend. Elevance Health pays out 29.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 15 consecutive years and Elevance Health has raised its dividend for 14 consecutive years.

Elevance Health has lower revenue, but higher earnings than Cencora. Elevance Health is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$337.40B	0.20	$3.48B	$17.92	20.04
Elevance Health	$199.13B	0.47	$5.66B	$23.45	18.32

Summary

Elevance Health beats Cencora on 11 of the 19 factors compared between the two stocks.

How does Cencora compare to McKesson?

Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Cencora has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, McKesson has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$337.40B	0.20	$3.48B	$17.92	20.04
McKesson	$403.43B	0.32	$4.76B	$38.89	28.37

McKesson has a net margin of 1.12% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat McKesson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	1.03%	110.72%	4.22%
McKesson	1.12%	-202.94%	5.92%

In the previous week, McKesson had 16 more articles in the media than Cencora. MarketBeat recorded 29 mentions for McKesson and 13 mentions for Cencora. McKesson's average media sentiment score of 0.98 beat Cencora's score of 0.83 indicating that McKesson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cencora	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
McKesson	20 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 0.4% of Cencora shares are owned by company insiders. Comparatively, 0.1% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cencora currently has a consensus target price of $368.14, suggesting a potential upside of 2.51%. McKesson has a consensus target price of $1,040.29, suggesting a potential downside of 5.71%. Given Cencora's higher probable upside, analysts plainly believe Cencora is more favorable than McKesson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75
McKesson	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.79

Cencora pays an annual dividend of $2.40 per share and has a dividend yield of 0.7%. McKesson pays an annual dividend of $3.76 per share and has a dividend yield of 0.3%. Cencora pays out 13.4% of its earnings in the form of a dividend. McKesson pays out 9.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 15 consecutive years and McKesson has raised its dividend for 17 consecutive years.

Summary

McKesson beats Cencora on 13 of the 19 factors compared between the two stocks.

How does Cencora compare to Henry Schein?

Cencora (NYSE:COR) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Cencora has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Cencora has higher revenue and earnings than Henry Schein. Cencora is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$337.40B	0.20	$3.48B	$17.92	20.04
Henry Schein	$13.18B	0.72	$398M	$3.65	23.62

In the previous week, Cencora had 12 more articles in the media than Henry Schein. MarketBeat recorded 13 mentions for Cencora and 1 mentions for Henry Schein. Cencora's average media sentiment score of 0.83 beat Henry Schein's score of 0.77 indicating that Cencora is being referred to more favorably in the media.

Company	Overall Sentiment
Cencora	Positive
Henry Schein	Positive

Henry Schein has a net margin of 3.07% compared to Cencora's net margin of 1.03%. Cencora's return on equity of 110.72% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	1.03%	110.72%	4.22%
Henry Schein	3.07%	16.39%	5.58%

Cencora currently has a consensus price target of $368.14, suggesting a potential upside of 2.51%. Henry Schein has a consensus price target of $93.57, suggesting a potential upside of 8.53%. Given Henry Schein's higher possible upside, analysts plainly believe Henry Schein is more favorable than Cencora.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.5% of Cencora shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.4% of Cencora shares are owned by company insiders. Comparatively, 0.9% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cencora beats Henry Schein on 9 of the 16 factors compared between the two stocks.

How does Cencora compare to AdaptHealth?

Cencora (NYSE:COR) and AdaptHealth (NASDAQ:AHCO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Cencora had 5 more articles in the media than AdaptHealth. MarketBeat recorded 13 mentions for Cencora and 8 mentions for AdaptHealth. Cencora's average media sentiment score of 0.83 beat AdaptHealth's score of 0.29 indicating that Cencora is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cencora	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AdaptHealth	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cencora has a net margin of 1.03% compared to AdaptHealth's net margin of -12.90%. Cencora's return on equity of 110.72% beat AdaptHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cencora	1.03%	110.72%	4.22%
AdaptHealth	-12.90%	-0.27%	-0.09%

Cencora has higher revenue and earnings than AdaptHealth. AdaptHealth is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$337.40B	0.20	$3.48B	$17.92	20.04
AdaptHealth	$3.24B	0.32	-$70.79M	-$3.00	N/A

Cencora currently has a consensus target price of $368.14, suggesting a potential upside of 2.51%. AdaptHealth has a consensus target price of $9.43, suggesting a potential upside of 23.09%. Given AdaptHealth's higher possible upside, analysts plainly believe AdaptHealth is more favorable than Cencora.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.75
AdaptHealth	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.5% of Cencora shares are held by institutional investors. Comparatively, 82.7% of AdaptHealth shares are held by institutional investors. 0.4% of Cencora shares are held by insiders. Comparatively, 2.0% of AdaptHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cencora has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, AdaptHealth has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Summary

Cencora beats AdaptHealth on 11 of the 15 factors compared between the two stocks.

Get Cencora News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COR vs. The Competition

Export

Metric	Cencora	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$66.67B	$10.82B	$7.84B	$23.48B
Dividend Yield	0.69%	2.54%	2.46%	3.78%
P/E Ratio	20.04	36.37	34.71	27.05
Price / Sales	0.20	2.15	8.66	3.38
Price / Cash	13.94	23.34	21.93	15.51
Price / Book	18.62	3.71	4.35	3.72
Net Income	$3.48B	$335.01M	$3.51B	$1.08B
7 Day Performance	7.72%	-1.06%	-1.49%	0.58%
1 Month Performance	6.93%	-0.57%	-2.55%	1.11%
1 Year Performance	-0.79%	21.17%	0.92%	7.21%

Cencora Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COR Cencora	4.6499 of 5 stars	$359.12 +2.8%	$368.14 +2.5%	-1.6%	$66.67B	$337.40B	20.04	51,000	Analyst Forecast
CAH Cardinal Health	3.522 of 5 stars	$273.95 +0.8%	$274.00 +0.0%	+36.7%	$63.43B	$257.75B	35.44	63,900	Dividend Announcement Analyst Forecast
ELV Elevance Health	4.705 of 5 stars	$417.73 -1.9%	$456.48 +9.3%	+30.9%	$90.26B	$199.13B	17.81	97,100	Positive News Analyst Forecast
MCK McKesson	4.1836 of 5 stars	$1,059.43 -0.1%	$1,026.18 -3.1%	+30.4%	$122.32B	$403.43B	27.24	43,000	Positive News Analyst Forecast
HSIC Henry Schein	2.152 of 5 stars	$88.42 +2.8%	$93.57 +5.8%	+17.6%	$9.77B	$13.18B	24.22	25,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:COR) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Competitors

COR vs. CAH, ELV, MCK, HSIC, and AHCO

How does Cencora compare to Cardinal Health?

Summary

How does Cencora compare to Elevance Health?

Summary

How does Cencora compare to McKesson?

Summary

How does Cencora compare to Henry Schein?

Summary

How does Cencora compare to AdaptHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COR vs. The Competition

Cencora Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cencora (COR) Competitors

COR vs. CAH, ELV, MCK, HSIC, and AHCO

How does Cencora compare to Cardinal Health?

Do insiders and institutionals have more ownership in CAH or COR?

Which has higher earnings & valuation, CAH or COR?

Is CAH or COR a better dividend stock?

Do analysts rate CAH or COR?

Is CAH or COR more profitable?

Which has more volatility & risk, CAH or COR?

Does the media favor CAH or COR?

Summary

How does Cencora compare to Elevance Health?

Is COR or ELV more profitable?

Does the media refer more to COR or ELV?

Which has more volatility and risk, COR or ELV?

Do analysts rate COR or ELV?

Do insiders & institutionals believe in COR or ELV?

Is COR or ELV a better dividend stock?

Which has better earnings & valuation, COR or ELV?

Summary

How does Cencora compare to McKesson?

Which has more risk & volatility, COR or MCK?

Which has stronger earnings & valuation, COR or MCK?

Is COR or MCK more profitable?

Does the media refer more to COR or MCK?

Do insiders & institutionals have more ownership in COR or MCK?

Do analysts prefer COR or MCK?

Is COR or MCK a better dividend stock?

Summary

How does Cencora compare to Henry Schein?

Which has more risk and volatility, COR or HSIC?

Which has preferable earnings and valuation, COR or HSIC?

Does the media refer more to COR or HSIC?

Is COR or HSIC more profitable?

Do analysts prefer COR or HSIC?

Do insiders & institutionals hold more shares of COR or HSIC?

Summary

How does Cencora compare to AdaptHealth?

Does the media refer more to COR or AHCO?

Is COR or AHCO more profitable?

Which has preferable valuation & earnings, COR or AHCO?

Do analysts recommend COR or AHCO?

Do insiders and institutionals have more ownership in COR or AHCO?

Which has more risk and volatility, COR or AHCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COR vs. The Competition

Cencora Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools